Rong Deng

5PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 27, 2024
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Chi-Chung Li, Brendan Bender, Justin Wilkins

|May 29, 2024
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Brendan Bender, Chi-Chung Li, Mathilde Marchand

|Dec 05, 2023
Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.

Yuan Chen, Fang Ma, Nicholas Jones

|Sep 24, 2021
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Bei Wang, Rong Deng, Stefanie Hennig

|Jun 09, 2021
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Bei Wang, Rong Deng, Stefanie Hennig

Pageof 1

Frequent Collaborators

4 joint publications

Bei Wang

4 joint publications

Chunze Li

3 joint publications

Chi-Chung Li

2 joint publications

Stefanie Hennig